https://scholars.lib.ntu.edu.tw/handle/123456789/564108
DC Field | Value | Language |
---|---|---|
dc.contributor.author | TUR-FU HUANG | en_US |
dc.contributor.author | Hsu C.-C. | en_US |
dc.contributor.author | Kuo Y.-J. | en_US |
dc.date.accessioned | 2021-05-31T07:03:13Z | - |
dc.date.available | 2021-05-31T07:03:13Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 14779560 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/564108 | - |
dc.description.abstract | Snake venoms affect blood coagulation and platelet function in a complex manner. However, two classes of venom proteins, snaclecs and disintegrins have been shown to specifically target receptors including GPIb, α2β1, GPVI, CLEC-2 and integrins αIIbβ3, αvβ3, α5β1 expressed on platelets, endothelial cells, phagocytes, tumor cells, thus affecting cell-matrices and cell-cell interactions. Here, we focus on disintegrins, a class of low molecular mass Arg-Gly-Asp(RGD)/Lys-Gly-Asp(KGD)-containing, cysteine-rich polypeptide derived from various viper snake venoms. This review describes the potential applications of disintegrins in field of integrin-related diseases, especially arterial thrombosis, angiogenesis, tumor progression and septic inflammation. In addition, a novel RGD-containing disintegrin TMV-7 is being developed as a safer antithrombotic agent with minimal side effects, such as thrombocytopenia and bleeding. ? 2016 The Author(s). | - |
dc.relation.ispartof | Thrombosis Journal | - |
dc.subject | Angiogenesis; Antithrombotic agent; Arterial thrombosis; Disintegrins; Septic inflammation; Snake venom proteins | - |
dc.subject.other | alphaIIb beta3 integrin; angiogenesis inhibitor; anticoagulant agent; antiinflammatory agent; antineoplastic agent; cilengitide; contortrostatin; disintegrin; eptifibatide; integrin; isotretinoin; rhodostomin; snake venom; tirofiban; tmv 7; trigramin; unclassified drug; very late activation antigen 2; very late activation antigen 5; very late activation antigen 6; vidapin; vimocin; angiogenesis; antigenicity; artery thrombosis; drug half life; drug potency; glioblastoma; hemostasis; human; non small cell lung cancer; Review; sepsis; structure activity relation; tumor growth | - |
dc.subject.other | [SDGs]SDG3 | - |
dc.title | Anti-thrombotic agents derived from snake venom proteins | en_US |
dc.type | review | - |
dc.identifier.doi | 10.1186/s12959-016-0113-1 | - |
dc.identifier.scopus | 2-s2.0-84990030026 | - |
dc.relation.pages | 18 | - |
dc.relation.journalvolume | 14 | - |
item.fulltext | no fulltext | - |
item.cerifentitytype | Publications | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.grantfulltext | none | - |
item.openairetype | review | - |
crisitem.author.dept | Pharmacology | - |
crisitem.author.orcid | 0000-0001-9252-938X | - |
crisitem.author.parentorg | College of Medicine | - |
Appears in Collections: | 藥理學科所 |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.